Annovis Bio (ANVS) has provided an update.
Annovis Bio, Inc. has received FDA approval to use a new crystal form of Buntanetap in upcoming clinical trials, marking a significant step forward for the company’s drug development efforts. This advancement is expected to intrigue those watching biotech stocks and could potentially influence the company’s market position.
See more insights into ANVS stock on TipRanks’ Stock Analysis page.
